Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $19.4 million.

  • Arcturus Therapeutics Holdings' Accumulated Expenses fell 4017.16% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year decrease of 4017.16%. This contributed to the annual value of $38.8 million for FY2024, which is 2164.3% up from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Accumulated Expenses stood at $19.4 million, which was down 4017.16% from $24.6 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' Accumulated Expenses' 5-year high stood at $52.4 million during Q3 2021, with a 5-year trough of $19.4 million in Q3 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $30.6 million (2025), whereas its average is $31.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 25861.31% in 2021, then tumbled by 5124.15% in 2022.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Accumulated Expenses stood at $23.5 million in 2021, then grew by 28.52% to $30.2 million in 2022, then grew by 5.45% to $31.9 million in 2023, then increased by 21.64% to $38.8 million in 2024, then crashed by 50.02% to $19.4 million in 2025.
  • Its last three reported values are $19.4 million in Q3 2025, $24.6 million for Q2 2025, and $30.6 million during Q1 2025.